Japanese approvals for Alexion, Eisai, Biocon

Drugs from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) and Eisai Co. Ltd. (Tokyo:4523) all received Japanese approval.

Alexion said Japan's Ministry of Health, Labour and Welfare (MHLW) approved Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D). The company said Kanuma is the first LAL-D treatment approved in Japan. It plans to launch the recombinant human LAL enzyme replacement therapy (ERT) in 3Q16. ...